Overview

Almorexant in Primary Insomnia

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to determine the minimum effective dose of ACT-078573 on sleep efficiency and to assess the effects of different doses of ACT-078573 on other PSG parameters.

Phase:

Phase 1

Details

Lead Sponsor:

Midnight Pharma, LLC